TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
Get Alerts TCRX Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David P. Southwell, President and Chief Executive Officer, will participate in a virtual panel discussion titled “A View to a Kill(er Cell)” at the 13th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022 at 1:10 p.m. ET.
A webcast of the panel discussion will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
Contacts:
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
[email protected]
Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BE Semiconductor Industries N.V. Announces Q1-24 Results
- Inside information: Meriaura Group's board has conditionally decided to sell Meriaura's minority ownership to Meriaura Invest to rearrange the group's financing
- Digitalist Group Plc’s Business Review, 1 January – 31 March 2024
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!